The campaign is launching alongside positive news for the company’s Phase 3 trials for a GBS treatment. Annexon Biosciences launched a new campaign to raise awareness with HCPs about the risk of ...
As Guillain-Barre Syndrome (GBS) cases rise, so does the social media buzz. Many theories are being floated on the dos and don’ts, which people are likely to believe. One such is avoiding meat. So, is ...
BRISBANE, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...
Guillain–Barré syndrome (GBS) is a heterogeneous disease characterized by rapidly progressive, symmetrical limb weakness with hyporeflexia or areflexia; sensory disturbances and cranial nerve deficits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results